Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease
In this small RCT of 12 months duration, octreotide slowed the progressive increase in liver and kidney volume in patients with polycystic kidney disease and polycystic liver disease. While the findings are encouraging and consistent with other studies, longer and larger clinical trials will be necessary to establish the long-term safety and efficacy of somatostatin analogs for ADPKD and/or ADPLD.
- Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease